Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the Phase III NALA trial of PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease, were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. “Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with = 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial,” was presented as an oral presentation by Adam M. Brufsky, MD, PhD, Professor of Medicine, Co-Director, Comprehensive Breast Cancer Center, Magee Women’s Hospital of the University of Pittsburgh Medical Center. Slides from the presentation are
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Puma Biotechnology (NASDAQ:PBYI) shareholders have earned a 93% return over the last year [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
PBYI
Earnings
- 2/29/24 - Miss
PBYI
Analyst Actions
- 2/13/24 - HC Wainwright
PBYI
Sec Filings
- 3/29/24 - Form SC
- 3/19/24 - Form 4
- 3/19/24 - Form 8-K
- PBYI's page on the SEC website